316 related articles for article (PubMed ID: 37237260)
1. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
2. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
3. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
4. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
[TBL] [Abstract][Full Text] [Related]
5. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
6. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
[TBL] [Abstract][Full Text] [Related]
9. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
[TBL] [Abstract][Full Text] [Related]
11. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ; Fervenza FC; Induruwage D; Brenchley PE; Rovin B; Hladunewich MA; Reich HN; Lafayette R; Aslam N; Appel GB; Zand L; Kiryluk K; Liu L; Cattran DC;
Clin J Am Soc Nephrol; 2023 Oct; 18(10):1283-1293. PubMed ID: 37471101
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in patients with membranous nephropathy and kidney insufficiency.
Guo Y; Wang L; Wang Y; Li X; Zhai Z; Yu L; Liang Y; Liu P; Tang L
Front Pharmacol; 2022; 13():1002117. PubMed ID: 36299887
[No Abstract] [Full Text] [Related]
13. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
16. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
[TBL] [Abstract][Full Text] [Related]
17. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
18. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
[TBL] [Abstract][Full Text] [Related]
19. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
20. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.
Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS
Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
